NL-OMON43643已完成2 期
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens - platinum sensitive serous ovarian cancer
Astra Zeneca0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Provision of voluntary obtained informed consent prior to any study specific procedures.
- •2. Female patients, > 18 years of age, with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer with a histology type of serous, or a serous component and who have completed at least 2 previous courses of platinum containing therapy (e.g. carboplatin or cisplatin)
- •3. Formalin fixed, paraffin embedded tumour sample from the cancer must be available for central testing.
排除标准
- •1. Patients with low grade ovarian carcinoma.
- •2. Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study.
- •3. Previous treatment with PARP inhibitors including AZD2281.
研究者
相似试验
进行中（未招募）
1 期
Assessment of efficacy of AZD2281 in Platinum Sensitive Serous OvarianCancerplatinum sensitive serous ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003439-18-PLAstraZeneca AB250
进行中（未招募）
1 期
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimensEUCTR2008-003439-18-EEAstraZeneca AB250
进行中（未招募）
不适用
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimensEUCTR2008-003439-18-FRAstraZeneca AB250
进行中（未招募）
不适用
Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimensEUCTR2008-003439-18-DEAstraZeneca AB250
进行中（未招募）
不适用
Assessment of efficacy of AZD2281 in Platinum Sensitive Serous Ovarian CancerEUCTR2008-003439-18-NLAstraZeneca AB250